Key Highlights

  • Bio-Gene Technology shares traded up 14.29% at $0.016 during the 11 November 2026 trading session.
  • The company is preparing documentation for the first commercial Supply of Qcide to Japan.
  • Draft toxicity study reports are under review, and the company completed its second Placement tranche.

Bio-Gene Technology Ltd (ASX:BGT) shares were trading at $0.016 during the session on 11 November 2026, up 14.29% by late morning. The S&P/ASX 200 (ASX:XJO) was down about 0.06% at 9,123.90 at 12:19 pm. Bio-Gene is an agtech company developing natural insecticides. On 30 October 2026, the company announced its activities and cash-flow results for the September 2026 quarter.

 

Preparations for Qcide Supply to Japan

The company said documentation and product development activities are under way to support the first commercial supply of its Qcide product to Japan. Bio-Gene’s managing director and chief executive attended major meetings in Japan and the United States during the quarter. The company also completed its 16th Qcide harvest at its north Queensland plantation.

 

Regulatory Studies and Flavocide Progress

Draft preliminary reports for the OECD 424 and OECD 443 toxicity studies are undergoing scientific and technical review before final results are released. Separately, the company said tick efficacy data for its Flavocide product was published in the peer-reviewed Journal Ticks and Tick-borne Diseases after the quarter ended. Bio-Gene also obtained grants and allowances for Flavocide Patent families covering combinations, resistant pests and aphid control.

 

Capital Raising and Cash Inflows

Bio-Gene completed the second Tranche of its placement and share purchase plan underwriting, bringing total gross proceeds to approximately $3.275 million. The company also received a $343,000 Research and Development tax incentive after the quarter ended, relating to eligible expenditure in FY26.

 

Sector Context

Agtech companies sit between agriculture and biotechnology, and their progress is usually tied to regulatory approvals, field trials and commercial partnerships. Shares in small-cap agricultural technology names tend to move on announcements about trials and customer supply, and at very low share prices they can rise or fall sharply on modest news.

 

Key Risks

Bio-Gene’s commercial plans depend on finalising regulatory documentation and completing the remaining studies. Final toxicity study results have not yet been released, and first supply to Japan remains at the preparation stage. The company’s funding depends on its ability to raise Capital while it works through these programs, and share prices at very low levels can be highly volatile.

 

What to Watch Ahead

Investors will be looking for the final OECD toxicity study results, progress on the first commercial supply arrangements for Qcide in Japan and the regulatory submission timetable for Flavocide in Australia. The company’s next Quarterly Report will provide an update on spending and on the status of these programs.

 

Final Word

Bio-Gene’s share price move on 11 November 2026 came as the company continues to advance its Qcide and Flavocide programs. The pace of regulatory and commercial progress from here will shape how the story develops over the coming quarters.